A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats

A. Bhatwadekar, J. V. Glenn, J. L. Figarola, S. Scott, T. A. Gardiner, S. Rahbar, A. W. Stitt

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. Methods: Streptozotocin- induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

Original languageEnglish (US)
Pages (from-to)545-547
Number of pages3
JournalBritish Journal of Ophthalmology
Volume92
Issue number4
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats'. Together they form a unique fingerprint.

  • Cite this